John Oyler Sells 4,940 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 4,940 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40. Following the transaction, the chief executive officer directly owned 1,120 shares of the company’s stock, valued at $303,027.20. This represents a 81.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ:ONC traded down $4.56 during mid-day trading on Wednesday, reaching $263.61. The stock had a trading volume of 291,079 shares, compared to its average volume of 255,249. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22. The business has a 50 day simple moving average of $301.03 and a 200 day simple moving average of $315.60. The firm has a market capitalization of $28.92 billion, a price-to-earnings ratio of 58.97 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EFG International AG purchased a new position in shares of BeOne Medicines in the fourth quarter valued at $25,000. Leonteq Securities AG purchased a new position in shares of BeOne Medicines in the fourth quarter valued at $35,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines in the second quarter valued at $35,000. CWM LLC increased its position in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new position in shares of BeOne Medicines in the fourth quarter valued at $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ONC has been the subject of a number of recent analyst reports. Barclays raised their target price on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wolfe Research assumed coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.